Middle East and Africa API Intermediates Market, By Type (Veterinary Drug Intermediates Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Middle East and Africa API Intermediates Market
Middle East and Africa API intermediates market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.3% in the forecast period of 2021 to 2028 and is expected to reach USD 1,188.62 million by 2028. High burden of chronic disorders and increase in aging population are the major drivers which propelled the demand of the market in the forecast period.
Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. The final drug dosage form is formulated using the APIs and excipient but the APIs are formulated using the raw material which is known as intermediates. API intermediates are the kind of material that is produced in the process of API. The intermediates are the by-product of the active pharmaceutical ingredients and provide the same therapeutic activity as that of APIs. These intermediates are also used to cure different kinds of chronic diseases such as cancers, respiratory diseases, and infectious diseases among others.
API intermediates are the agents or compounds that are used as raw materials for the formulation or production of active pharmaceutical ingredients. These intermediates go under refinement or molecular changes to form a final API. Different technologies such as amination, alkoxylation, electrochemistry, hydrogenation, hydroformylation, acetylene chemistry, phosgene chemistry, and other technologies are involved in the production of intermediates.
The API intermediates market is growing with the increasing prevalence of various chronic disorders and the increasing aging population. Moreover, increasing research and development regarding pharmaceutical APIs and their intermediates are other factors accelerating the API intermediates market growth.
The API intermediates market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa API Intermediates Market Scope and Market Size
API intermediates market is segmented on the based on the basis of type, product, therapeutic type, customers, end users, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, API intermediates market is segmented into veterinary drug intermediates pharmaceutical / bulk drug intermediates. In 2021, pharmaceutical / bulk drug intermediates is expected to dominate the API intermediates market due to rising demand of APIs for the production of finished goods and rising prevalence of various diseases which required continues production of drugs.
- On the basis of product, API intermediates market is segmented into bromo compound, O-benzyl salbutamol, hemisulfate, oxirane, bisoprolol base, chiral PCBHP, pheniramine base, chlorpheniramine base, brompheniramine base, mepyramine/pyrilamine base, 6-amino-1,3-dimethyl uracil, theofylline, acefylline, xanthine, nitriles, and others. In 2021, nitriles segment is expected to dominate the API intermediates market due to the high cost of the products and continues research and development for the innovative APIs.
- On the basis of therapeutic type, API intermediates market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, urology, and others. In 2021, cardiovascular diseases segment is expected to dominate the API intermediates market because cardiovascular is the leading cause of death globally.
- On the basis of customers, API intermediates market is segmented direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/Pvt institutions. In 2021, direct users/pharma companies segment is expected to dominate the API intermediates market because APIs manufacture are the primary and direct user for the intermediates. Rising Contract manufacturing also boost the market.
- On the basis of end user, API intermediates market is segmented into API manufacturer, and finished product manufacturer. In 2021, API manufacturer segment is dominating the API intermediates market because intermediates are the primary chemical substrate of the APIs, which can be further converted in APIs. So, the intermediates is widely used by the API manufacturer to reduce the cost of manufacturing.
- On the basis of distribution channel, API intermediates market is segmented into direct tender, retail sales, and others. In 2021, direct tender is expected to dominate the API intermediates market because direct tender provides huge margin for the purchase good and direct tender has competitive selection of contract and consultants there is accountability.
API Intermediates Market Country Level Analysis
The API intermediates market is analyzed and market size information is provided on the basis of type, product, therapeutic type, customers, end users, and distribution channel as referenced above.
The countries covered in the API intermediates market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa.
Saudi Arabia is leading the growth of the Middle East and Africa region due to increasing prevalence of various chronic disorders in the country.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Research and Development Regarding Pharmaceutical APIs and their intermediates and Increasing Disease Awareness and Education are boosting the Market Growth of API Intermediates
API intermediates market also provides you with detailed market analysis for every country growth in API intermediates industry with API intermediates drugs sales, impact of advancement in the API intermediates technology and changes in regulatory scenarios with their support for the API intermediates market. The data is available for historic period 2010 to 2019.
Competitive Landscape and API intermediates Market Share Analysis
API intermediates market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to API intermediates market.
The major companies which are dealing in the API intermediates are Sanofi, Aurobindo Pharma, BASF SE, Vasudha Pharma, Anyang General Chemical Co.,Ltd., Sandoo Pharmaceuticals and Chemicals Co., Ltd., Atul Ltd., Supriya Lifescience Ltd. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the API intermediates market.
For instance,
- In November 2020, AlzChem Group AG had announced the expansion of the production of the nitriles which is one of the intermediates of the company. The company has decided to expand the production by 50%. The motive behind the company was to support the demand of the medicines and biocides. The nitrile production plant is based on the gas phase technology which has been optimized and validated by the company’s engineers. This expansion has helped the company to enhance their growth in the field of the intermediates which will help them to boost their production capacities.
- In April 2020, Aceto has announced the acquisition of Syntor Fine Chemicals who is one of the leading manufacturers of fine-chemicals which is used for the pharma industries and life-sciences end markets. This acquisition helped the company to increase their market growth as Syntor Fine Chemicals will provide their in-house developed products to the company therefore, both the companies will work together to meet the increase demand of the customers.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the API intermediates market which also provides the benefit for organization to improve their offering for API intermediates.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 CURRENT SCENARIO OF IMPORT AND EXPORT OF API INTERMEDIATE
4.2 TENTATIVE PRODUCTION AND OPERATIONAL COSTS CALCULATIONS WHICH WILL ULTIMATELY LEAD TO FEASIBILITY OF THE PRODUCT MANUFACTURING
4.2.1 TENTATIVE LAND REQUIREMENT FOR A SUBSTANTIAL PRODUCTION CAPACITY PLANT SET-UP
4.3 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: 3C ANALYSIS-CHINA EFFECT
4.3.1 THE U.S.-CHINA TRADE WAR
4.3.2 INDO-CHINA GEOPOLITICAL ISSUES
4.3.3 CHINESE SLOWDOWN DUE TO E&C OVER THE YEARS
4.3.4 CHINESE SLOWDOWN DUE TO COVID-19 (CORONAVIRUS)
4.4 COST ANALYSIS
4.5 ANALYSIS ON CHINA API INTERMEDIATES:
4.5.1 CONCLUSION:
4.6 PORTERS FIVE FORCES MODEL
4.7 PESTEL ANALYSIS
4.8 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: REGULATORY
4.8.1 THE U.S. REGULATORY GUIDANCE FOR NON-CLINICAL SAFETY EVALUATION OF API INTERMEDIATES
4.8.2 CANADA REGULATORY GUIDANCE FOR API INTERMEDIATES
4.8.3 EUROPE REGULATORY SCENARIO FOR API INTERMEDIATES
4.8.4 JAPAN REGULATORY FOR API INTERMEDIATES
4.8.5 MIDDLE EAST AND AFRICA REGULATORY FRAMEWORK FOR API INTERMEDIATES
5 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: CONCLUSION
5.1 TOP PRODUCTS AND THERAPEUTIC AREAS
5.2 ADDITIONAL
6 CUSTOMER SENTIMENTS/INCLINATION TOWARDS FINDING ALTERNATE VENDOR SOURCE
7 LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH BURDEN OF CHRONIC DISEASES
8.1.2 INCREASE IN AGING POPULATION
8.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING
8.1.4 INCREASING DISEASE AWARENESS AND EDUCATION
8.1.5 RESEARCH AND DEVELOPMENT REGARDING PHARMACEUTICAL API AND THEIR INTERMEDIATES
8.2 RESTRAINTS
8.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS
8.2.2 PRODUCT RECALLS
8.2.3 HIGH MANUFACTURING COST
8.2.4 STRINGENT GOVERNMENT REGULATIONS FOR API INTERMEDIATES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
8.3.2 INCREASING HEALTHCARE EXPENDITURE
8.3.3 SOARING NUMBER OF API INTERMEDIATES MANUFACTURERS
8.3.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO)
8.4 CHALLENGES
8.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19
8.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
9 IMPACT OF COVID 19 ON MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE
9.5 CONCLUSION
10 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY TYPE
10.1 OVERVIEW
10.2 PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES
10.3 VETERINARY DRUG INTERMEDIATES
11 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 NITRILES
11.3 BROMO COMPOUND
11.4 CHIRAL PCBHP
11.5 CHLORPHENIRAMINE BASE
11.6 BROMPHENIRAMINE BASE
11.7 PHENIRAMINE BASE
11.8 O-BENZYL SALBUTAMOL
11.9 BISOPROLOL BASE
11.1 HEMISULFATE
11.11 OXIRANE
11.12 MEPYRAMINE/PYRILAMINE BASE
11.13 THEOFYLLINE
11.14 ACEFYLLINE
11.15 XANTHINE
11.16 6-AMINO-1,3-DIMETHYL URACIL
11.17 OTHERS
12 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE
12.1 OVERVIEW
12.2 CARDIOVASCULAR DISEASES
12.3 METABOLIC DISEASES
12.4 INFECTIOUS DISEASES
12.5 RESPIRATORY DISEASES
12.6 NEUROLOGY
12.7 ONCOLOGY
12.8 AUTOIMMUNE DISEASE
12.9 DERMATOLOGY
12.1 OPHTHALMOLOGY
12.11 UROLOGY
12.12 OTHERS
13 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS
13.1 OVERVIEW
13.2 DIRECT USERS/PHARMA COMPANIES
13.3 TRADERS/WHOLESALERS/DISTRIBUTORS
13.4 ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONS
14 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY END USER
14.1 OVERVIEW
14.2 API MANUFACTURER
14.3 FINISHED PRODUCT MANUFACTURER
15 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALE
15.4 OTHERS
16 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET BY GEOGRAPHY
16.1 MIDDLE EAST & AFRICA
16.1.1 SAUDI ARABIA
16.1.2 SOUTH AFRICA
16.1.3 UAE
16.1.4 ISRAEL
16.1.5 KUWAIT
16.1.6 EGYPT
16.1.7 REST OF MIDDLE EAST & AFRICA
17 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 AUROBINDO PHARMA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 DIVI’S LABORATORIES LIMITED
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 BASF SE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 CAMBRIX CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ACETO
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 HIKAL LTD.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALZCHEM GROUP AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 VERTELLUS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT CATEGORIES
19.9.3 RECENT DEVELOPMENTS
19.1 SANOFI
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 ATUL LTD
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 AARTI INDUSTRIES LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 VASUDHA PHARMA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 ANYANG GENERAL CHEMICAL CO., LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 DISHMAN CARBOGEN AMICS LTD
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 GANESH-GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENTS
19.17 LEVACHEM COMPANY LIMITED
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SANDOO PHARMACEUTICALS AND CHEMICALS CO., LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 SAREX
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 SUPRIYA LIFESCIENCE LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: CUSTOMIZATION (COUNTRIES INVOLVED IN IMPORT & EXPORT)
TABLE 2 PERCENTAGE BREAK UP OF COST
TABLE 3 TENTATIVE LAND REQUIREMENT
TABLE 4 PERCENTAGE BREAK UP OF PLANT AREA
TABLE 5 TABLE: 1 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE
TABLE 6 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 7 MARKET PLAYERS OF API INTERMEDIATES
TABLE 8 SALES DATA OF API INTERMEDIATES FOR 2019/2020
TABLE 9 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA VETERINARY DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA NITRILES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA BROMO COMPOUND IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CHIRAL PCBHP IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA CHLORPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA BROMPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA PHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA O-BENZYL SALBUTAMOL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA BISOPROLOL BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA HEMISULFATE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA OXIRANE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA MEPYRAMINE/PYRILAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA THEOFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA ACEFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA XANTHINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA 6-AMINO-1, 3-DIMETHYL URACIL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA METABOLIC DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICAINFECTIOUS DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA NEUROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA ONCOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA DERMATOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA OPHTHALMOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA UROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA DIRECT USERS/PHARMA COMPANIES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA TRADERS/WHOLESALERS/DISTRIBUTORS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA API MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA FINISHED PRODUCT MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA DIRECT TENDER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA RETAIL SALES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA OTHERSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 SAUDI ARABIA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 SAUDI ARABIA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 61 SAUDI ARABIA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 62 SAUDI ARABIA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 63 SAUDI ARABIA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 SAUDI ARABIA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 UAE API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 UAE API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 UAE API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 74 UAE API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 75 UAE API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 76 UAE API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 77 ISRAEL API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 ISRAEL API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 79 ISRAEL API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 80 ISRAEL API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 81 ISRAEL API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 82 ISRAEL API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 83 KUWAIT API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 KUWAIT API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 85 KUWAIT API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 86 KUWAIT API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 87 KUWAIT API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 88 KUWAIT API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 89 EGYPT API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 EGYPT API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 91 EGYPT API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 92 EGYPT API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 93 EGYPT API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 EGYPT API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 REST OF MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: MARKET TYPE COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: SEGMENTATION
FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING IS DRIVING THE MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PHARMACEUTICAL / BULK DRUG INTERMEDIATES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET
FIGURE 15 TOP 5 COUNTRIES FOR NUMBER OF PEOPLE AGED 20 TO 79 SUFFERING FROM DIABETES IN 2019
FIGURE 16 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN FEMALE POPULATION IN 2020
FIGURE 17 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN MALE POPULATION IN 2020
FIGURE 18 MIDDLE EAST AND AFRICA CAUSES OF DEATHS WITH THE CHRONIC DISEASES
FIGURE 19 NUMBER OF PERSON AGED 60 YEARS OR OVER BY REGIONS IN 2020 (IN MILLIONS)
FIGURE 20 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 21 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, 2021
FIGURE 22 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 24 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, 2021
FIGURE 26 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, 2019-2028 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, CAGR(2021-2028)
FIGURE 28 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2021
FIGURE 30 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, CAGR (2021-2028)
FIGURE 32 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2021
FIGURE 34 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2019-2028 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, CAGR (2021-2028)
FIGURE 36 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, 2021
FIGURE 38 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 39 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, CAGR (2021-2028)
FIGURE 40 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 42 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 43 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 44 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: SNAPSHOT (2020)
FIGURE 46 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY COUNTRY (2020)
FIGURE 47 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 48 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 49 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY TYPE (2021-2028)
FIGURE 50 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.